Anyone know where this trial is taking place? Almost impossible to ethically conduct this kind of study in many countries given success of Lucentis/Avastin.
<TargeGen, Inc. today announced that the Company has initiated a multi-center Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD). >
Market Data 
Markets 
AI
